Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

I want to receive updates from fenix.group.

By selecting this, I agree to receive emails from fenix.group.

Processing...

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

RETURN TO HOME

$599

Insulin Delivery, SGLT2i

December 17, 2019

Medtronic Acquires Klue; New Tandem SGLT2i+Closed-loop Trial

Here is a brief preview of this blast: Medtronic announced it has completed the acquisition of "Klue," a company developing behavior tracking technology to "provide real-time insights into when a person is consuming food." Additionally, a new CT.gov record has been observed for an investigator-initiated trial evaluating Tandem's closed-loop systems (Basal IQ and Control IQ) in T1DM patients on an SGLT2i. Below, FENIX provides thoughts on the news items including how Klue may help to enhance Medtronic's PCL while still leaving some potential hurdles.